Literature DB >> 34657475

Stability of maternal serum free β-hCG following whole blood sample transit: First trimester Down's syndrome screening in Scotland.

Angela Ballantyne1, Lorna Rashid1, Rebecca Pattenden1.   

Abstract

BACKGROUND: Maternal serum free beta human chorionic gonadotrophin (free β-hCG) is used as a biomarker in first trimester screening for fetal Down's syndrome. Production of free β-hCG can occur in vitro in a time- and temperature-dependent manner; thus, the current Scottish screening protocol states samples must be received by the laboratory within 72 h. To assess the validity of the protocol, an audit was conducted to determine the impact of transit time on maternal serum free β-hCG multiple of median (MoM) values in the Scottish screened population.
METHODS: Corrected MoM values from antenatal screening carried out over one year (April 2017 to March 2018) were stratified according to sample transit time and compared. To investigate possible environmental temperature effects, the data were split according to season and maternal serum free β-hCG concentrations from summer and winter compared.
RESULTS: Of the 28,368 samples included in the study, 24,368 were received on the day of phlebotomy or after one day in transit. Only 1.5% of samples were received after 3 days in transit. The difference in maternal serum free β-hCG MoM values due to transit time was not significant. No statistical difference was found between maternal serum free β-hCG concentrations from samples collected in summer and winter months.
CONCLUSION: The current sample receipt protocol in use by the Scottish Down's syndrome screening programme is fit for purpose.

Entities:  

Keywords:  Pregnancy; statistics

Mesh:

Substances:

Year:  2021        PMID: 34657475     DOI: 10.1177/00045632211045250

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  1 in total

Review 1.  Human Chorionic Gonadotropin and Early Embryogenesis: Review.

Authors:  Sophie Perrier d'Hauterive; Romann Close; Virginie Gridelet; Marie Mawet; Michelle Nisolle; Vincent Geenen
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.